Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 2/20 | 0.60 |
| ▸ | HTR2A | P28223 | 3/20 | 0.53 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.52 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.52 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.50 |
| ▸ | HTR1B | P28222 | 1/20 | 0.50 |
| ▸ | HRH1 | P35367 | 1/20 | 0.50 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.50 |
| ▸ | HTR6 | P50406 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12809959 | 0.95 | HTR2C (0.66) | HTR2CHTR2AHTR6 | |
| Hydrochloric Acid SCHEMBL568208 | 0.93 | HTR2C (0.67) | HTR2CHTR2AHTR6 | |
| SCHEMBL1811550 | 0.86 | HTR2C (0.79) | HTR2CHTR2AP2RY14TMEM97 | |
| SCHEMBL17938547 | 0.86 | HTR2C (0.79) | HTR2CHTR2AP2RY14TMEM97 | |
| SCHEMBL16660400 | 0.86 | HTR2C (0.79) | HTR2CHTR2AP2RY14TMEM97 | |
| Hydrochloric Acid SCHEMBL4573167 | 0.85 | HTR2C (0.80) | HTR2CHTR2AP2RY14TMEM97 | |
| SCHEMBL22778149 | 0.81 | KCNH2 (0.55) | HTR2CHTR2AHRH1 | |
| SCHEMBL15650799 | 0.81 | HTR2A (0.54) | HTR2CHTR2AHTR6 | |
| SCHEMBL23817068 | 0.81 | HTR2C (0.59) | HTR2CHTR2AP2RY14TMEM97ADRB3 | |
| SCHEMBL22795541 | 0.80 | MAPK11 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12115154-B2 | Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) | SRX CARDIO, LLC (US) | 2024-10-15 | — | — | US | disclosed |
| US-20220267269-A1 | COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | SRX CARDIO LLC (US) | 2022-08-25 | — | — | US | disclosed |
| US-20220193058-A1 | COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | SRX CARDIO, LLC | 2022-06-23 | — | — | US | disclosed |
| EP-3983392-A2 | COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | SRX Cardio, LLC (US) | 2022-04-20 | — | — | EP | disclosed |
| WO-2020252383-A2 | COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | SRX CARDIO, LLC (US) | 2020-12-17 | — | — | WO | disclosed |
| WO-2020252383-A2 | COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | SRX CARDIO, LLC (US) | 2020-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220193058-A1 | COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | HTR2C 3722/4885HTR2A 3413/4885P2RY14 3835/4885 |
| US-12115154-B2 | Compounds for the modulation of proprotein convertase subtilisin/kexin type 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | HTR2C 3722/4885HTR2A 3413/4885P2RY14 3835/4885 |
| US-20220267269-A1 | COMPOUNDS FOR THE MODULATION OF PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) | PCSK9, PCSK6, PCSK7 | HTR2C 3722/4885HTR2A 3413/4885P2RY14 3835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.